Alvesco now available for asthma sufferers in britain Altana AG has announced that Alvesco.

IMS data reveal that the UK may be the largest marketplace in Europe for asthma medicine. The market in mono-therapy inhaled corticosteroids represented a value of some EUR1 billion in 2003, of which the UK accounted for about 30 %. Hans-Joachim Lohrisch, President and CEO of Altana Pharma. As well as the launched inhaler Alvesco, that cooperation partner sanofi-aventis has recently filed a credit card applicatoin in the U.S. And cooperation partner Teijin in Japan, the family also includes Ciclesonide nasal spray , Ciclesonide as a fixed combination product with formoterol and Ciclesonide as a dry powder inhaler .The study comprised three two-week periods: baseline, changeover to PaQ, and PaQ treatment period. CeQur expects to talk about initial results early following year. Related StoriesBariatric surgery improves excess weight, metabolic health and quality of life in adolescents after 3 yearsHeart attack patients diagnosed and treated for diabetes knowledge improved cardiac outcomesStudy explores diabetes screening for sufferers with serious mental illnessPaQ is usually a discreet, wearable device that delivers three days of consistent, basal insulin delivery along with easy, on-demand bolus insulin.

Other entries from category "rheumatology":

Random entries